PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

insulin glargine

Verify with FDA → · CMS NADAC pricing →

Brand names: Lantus, Basaglar, Toujeo

Long-Acting Insulin Rx

Basaglar is a long-acting insulin that helps control blood sugar levels. It is used to treat type 1 and type 2 diabetes.

Drug Shortage Alert

insulin glargine is currently listed as to be discontinued by the FDA. Affected manufacturer: Eli Lilly and Co..

View all drug shortages →

Drug Pricing (NADAC)

Brand Price

$20.94/unit

Generic Price

$8.95/unit

Generic Savings

57%

Generic Available

Yes (0 manufacturers)

Pricing data from NADAC (CMS), effective December 18, 2024. Compare all drug costs →

What it does

Basaglar is used to lower blood sugar in adults and children with type 1 diabetes.

Common side effects

Low blood sugar (hypoglycemia), Allergic reactions, Injection site reactions (redness, swelling, itching)

Key warnings

Never share your Basaglar pen with anyone else, even if you change the needle.

How It Works

Basaglar is a long-acting form of insulin. It works by replacing the insulin that your body does not make, or helping your body use insulin better. This helps to lower your blood sugar levels over a longer period.

How to Take It

Inject Basaglar under your skin once a day, at the same time each day. You can inject it at any time of day. Your doctor will tell you how much Basaglar to use based on your needs. Always check the insulin label before you inject it.

Pregnancy & Breastfeeding

Talk to your doctor if you are pregnant or plan to become pregnant. Poorly controlled diabetes during pregnancy can harm both the mother and the baby. Basaglar's effects during pregnancy are not well-studied.

Missed Dose

If you miss a dose of Basaglar, inject it as soon as you remember. Then, go back to your regular injection schedule.

Storage

Keep unopened Basaglar pens in the refrigerator or at room temperature for up to 28 days. Opened pens should be stored at room temperature and used within 28 days.

Side Effects (from patient reports)

Based on 121,395 FDA adverse event reports.

Increased blood sugar
38,213
Using the medicine for something it's not approved for
11,495
Decreased blood sugar
10,314
The medicine is not working
10,279
Taking the medicine at the wrong time
9,798
Feeling sick to your stomach
9,566
The medicine was stored incorrectly
8,531
Vision problems
8,514
Low blood sugar
7,787
Loose stools
6,898

FDA Adverse Event Report Analysis

Detailed analysis of 236,147 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2001–2025.

Total Reports

236,147

Death-Related Reports

13,233

Hospitalization Reports

62,916

Top Indication

Type 2 Diabetes Mellitus

Gender Distribution

Female 120,021 (55%)
Male 98,721 (45%)

Age Distribution

0–17 2,493
18–44 12,380
45–64 57,639
65–74 46,118
75+ 34,616

Most Reported Adverse Reactions (FAERS)

# Reaction Reports
1 BLOOD GLUCOSE INCREASED 38,214
2 OFF LABEL USE 11,496
3 BLOOD GLUCOSE DECREASED 10,314
4 DRUG INEFFECTIVE 10,281
5 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 9,798
6 NAUSEA 9,568
7 PRODUCT STORAGE ERROR 8,531
8 VISUAL IMPAIRMENT 8,514
9 HYPOGLYCAEMIA 7,786
10 DIARRHOEA 6,900
11 FATIGUE 6,761
12 INCORRECT DOSE ADMINISTERED 6,540
13 MALAISE 6,531
14 WEIGHT DECREASED 6,309
15 INJECTION SITE PAIN 6,248

Reactions in Death Reports

DEATH 4,520
RENAL FAILURE 834
ACUTE KIDNEY INJURY 657
DYSPNOEA 633
MYOCARDIAL INFARCTION 605
PNEUMONIA 600
CARDIAC ARREST 555
SEPSIS 546
RESPIRATORY FAILURE 416
CHRONIC KIDNEY DISEASE 415

Reactions in Hospitalization Reports

BLOOD GLUCOSE INCREASED 6,484
HYPOGLYCAEMIA 3,745
FALL 3,584
DYSPNOEA 3,460
NAUSEA 3,426
PNEUMONIA 3,306
VOMITING 3,207
DIARRHOEA 2,895
ACUTE KIDNEY INJURY 2,798
ASTHENIA 2,642

Source: FDA FAERS (Adverse Event Reporting System) FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation

Serious Warnings

Never share your Basaglar pen with anyone else, even if you change the needle. Sharing pens can spread blood-borne diseases. Changes to your insulin plan can affect your blood sugar. Make sure a doctor supervises any changes and that you check your blood sugar often. Low blood sugar can be very dangerous and even life-threatening. Watch for symptoms and check your blood sugar often. Low potassium can also be life-threatening. Tell your doctor if you have heart problems or take certain diabetes medicines called thiazolidinediones, as this can lead to heart failure.

Known Drug Interactions

moderate fluoxetine

7 DRUG INTERACTIONS Table 6 includes clinically significant drug interactions with BASAGLAR Table 6: Clinically Significant Drug Interactions with BASAGLAR Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, d...

Mechanism: Fluoxetine can increase the effect of insulin, which may cause your blood sugar to drop lower than expected.

What to do: Watch for signs of low blood sugar and talk to your doctor about adjusting your medication doses.

moderate pramlintide

7 DRUG INTERACTIONS Table 6 includes clinically significant drug interactions with BASAGLAR Table 6: Clinically Significant Drug Interactions with BASAGLAR Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, d...

Mechanism: Both medications are used to lower blood sugar, so using them at the same time increases the risk of hypoglycemia.

What to do: Your healthcare provider may need to adjust your insulin dose and you should monitor your blood sugar levels frequently.

moderate octreotide

7 DRUG INTERACTIONS Table 6 includes clinically significant drug interactions with BASAGLAR Table 6: Clinically Significant Drug Interactions with BASAGLAR Drugs That May Increase the Risk of Hypoglycemia Drugs: Antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, disopyramide, fibrates, fluoxetine, monoamine oxidase inhibitors, pentoxifylline, pramlintide, salicylates, somatostatin analogs (e.g., octreotide), and sulfonamide antibiotics. Drugs that may increase the risk of hypoglycemia: antidiabetic agents, ACE inhibitors, angiotensin II receptor blocking agents, d...

Mechanism: Octreotide can lower blood sugar levels, which adds to the effect of insulin and increases the risk of a dangerous drop.

What to do: Check your blood sugar levels often and consult your doctor about changing your insulin dose.

Drugs That May Decrease the Blood Glucose Lowering Effect of BASAGLAR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones Intervention: Dose increases and increased frequency of glucose monitoring may be required when BASAGLAR is co-administered with these drugs. Drugs that may decrease the blood gluco...

Mechanism: Albuterol is a stimulant-like drug that can raise blood sugar, making your insulin work less effectively.

What to do: Check your blood sugar more often and talk to your doctor about whether your insulin dose needs to be increased.

Drugs That May Increase or Decrease the Blood Glucose Lowering Effect of BASAGLAR Drugs: Alcohol, beta-blockers, clonidine, and lithium salts. Drugs That May Blunt Signs and Symptoms of Hypoglycemia Drugs: beta-blockers, clonidine, guanethidine, and reserpine Intervention: Increased frequency of glucose monitoring may be required when BASAGLAR is co-administered with these drugs. Drugs that may increase or decrease the blood glucose lowering effect: alcohol, beta-blockers, clonidine, lithium salts, and pentamidine ( 7 ).

Mechanism: Clonidine can cause blood sugar to go up or down and can also hide the physical signs that your blood sugar is too low.

What to do: You should monitor your blood sugar more frequently since you may not notice the usual warning signs of a sugar drop.

Check all your medications →

Common Questions

Can I mix Basaglar with other insulins?
No, do not mix or dilute Basaglar with any other insulin or solution.
Where should I inject Basaglar?
Inject Basaglar under the skin of your stomach area, thigh, or upper arm. Change your injection site each time.
How often should I check my blood sugar?
Check your blood sugar as often as your doctor tells you to. This is very important when you start Basaglar or make changes to your dose.
What should I do if my blood sugar is too low?
Treat low blood sugar right away by eating or drinking something sugary. Check your blood sugar again after 15 minutes. Contact your doctor if low blood sugar happens often.
What should I do if my blood sugar is too high?
Follow your doctor's instructions for treating high blood sugar. This may include taking more insulin or changing your diet.
Can I use Basaglar in an insulin pump?
No, do not use Basaglar in an insulin pump.
What if I have vision problems?
Use Basaglar with caution if you have vision problems. Get help if you have trouble dialing your dose.
How do I dispose of used Basaglar pens?
Dispose of used Basaglar pens safely in a sharps container. Do not throw them in the trash.
What if I travel?
When traveling, keep Basaglar with you and protect it from extreme temperatures. Bring extra insulin and supplies.
What do I do if my Basaglar pen is damaged?
Do not use a Basaglar pen if it is damaged. Contact your pharmacist or doctor for a replacement.
What are the common side effects of insulin glargine?
The most commonly reported side effects of insulin glargine include Low blood sugar (hypoglycemia), Allergic reactions, Injection site reactions (redness, swelling, itching), Skin thickening or pits at the injection site, Itching. Based on 121,395 FDA adverse event reports. Always consult your healthcare provider about potential side effects.
Does insulin glargine interact with other medications?
Yes, insulin glargine has 11 known drug interactions. Notable interactions include fluoxetine, pramlintide, octreotide. Always inform your doctor about all medications you are taking.
What drug class is insulin glargine?
insulin glargine belongs to the Long-Acting Insulin drug class. It requires a prescription (Rx). Basaglar is used to lower blood sugar in adults and children with type 1 diabetes.
Is there a generic version of insulin glargine?
Yes, generic insulin glargine is available. The generic costs $8.95 per unit compared to $20.94 for the brand version, saving approximately 57%. Pricing is based on NADAC (National Average Drug Acquisition Cost) data from CMS.
Is insulin glargine safe during pregnancy?
Talk to your doctor if you are pregnant or plan to become pregnant. Poorly controlled diabetes during pregnancy can harm both the mother and the baby. Always consult your healthcare provider before using any medication during pregnancy or breastfeeding.
Is insulin glargine currently in shortage?
Yes, insulin glargine is currently listed as to be discontinued by the FDA. Affected manufacturer: Eli Lilly and Co.. Visit the FDA Drug Shortages database for the latest updates.

Related Medications in Long-Acting Insulin

Other drugs grouped near insulin glargine — same-class peers and common alternatives.

Compare insulin glargine vs acarbose side-by-side →

Medication Guides

Related Health & Safety Data

Save on insulin glargine

Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.

Disclosure: This link may earn us a commission at no extra cost to you. See our terms.

What the FDA Data Shows for insulin glargine

The FDA label for insulin glargine (sold under brand names such as Lantus, Basaglar, Toujeo) classifies it as a prescription-only medication in the Long-Acting Insulin class. Basaglar is used to lower blood sugar in adults and children with type 1 diabetes. Official labeling lists 11 commonly reported side effects, including Low blood sugar (hypoglycemia), Allergic reactions, Injection site reactions (redness, swelling, itching).

Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 121,395 voluntary reports. The database also lists 11 documented drug interactions derived from FDA labeling, with the top-flagged interaction rated moderate severity. NADAC pricing from CMS shows a generic unit cost of $8.95 versus $20.94 for the brand — a 57% generic savings.

Report counts do not establish causation — a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information further shape supply and switching decisions. This page summarizes public FDA data for educational purposes only and is not a substitute for professional medical advice — always consult a licensed healthcare provider before starting, stopping, or changing any medication.

Data Sources

Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS). Pricing: CMS National Average Drug Acquisition Cost (NADAC). Shortage status: FDA Drug Shortages Database.

FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. Always consult a healthcare professional before making medication decisions.

Last updated: December 11, 2025

All federal data sources used on this page